UNSPSC 51111613: Lenograstim

This classification denotes a recombinant protein and Immunologic adjuvant with the molecular formula C9H14N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6WS4C399GB. European Medicines Agency schedules Lenograstim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02888MIG. The term LENOGRASTIM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31.).

World Health Organization schedules lenograstim in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule lenograstim under HS 30012010 and SITC 54162. As of Q4 2014, LENOGRASTIM remains the US FDA Preferred Term for this commodity. Lenograstim bears US NLM identifiers UMLS ID C0218640 and NCI Concept Code C49234. SMILES: N/A.

UNSPSC 51111613 Lenograstim is a Commodity code for a specific granulocyte colony-stimulating factor (G-CSF) pharmaceutical product. State and local procurement activity under this code reflects health agencies' sourcing of lenograstim as a component of pharmacy benefit programs and formulary management, typically through direct-to-manufacturer or group purchasing arrangements that balance cost, access, and clinical outcomes. The issuing body in the recent activity is a state health agency — the Texas Health and Human Services Commission — exploring vendor capacity to establish direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager intermediaries.

The Texas Health and Human Services Commission issued Request for Information (RFI) No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, to assess vendor capability for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI sought information on vendors' experience with direct contracting for self-insured employers and government health plans, flexibility to negotiate net pricing models, and capacity to implement value-based or outcomes-based agreements. No award value, budget range, or formal evaluation criteria were specified at the RFI stage; the procurement functions as market intelligence to inform the state's future procurement strategy before issuing a formal RFP.